Wellstat Therap patents expiration
1. Vistogard patents expiration
VISTOGARD Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | WELLSTAT THERAP | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(2 months ago) | |
| US7776838 | WELLSTAT THERAP | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 11, 2022 |
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
More Information on Dosage
VISTOGARD family patents
2. Xuriden patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | WELLSTAT THERAP | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 4, 2022 |
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 04 September, 2015
Treatment: NA
Dosage: GRANULE;ORAL
More Information on Dosage
XURIDEN family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic